Neurology · Clinical trials
Friedreich's Ataxia Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About friedreich's ataxia — and why its trials are hard
Friedreich's ataxia (FA) is a rare, autosomal-recessive neurodegenerative disorder caused by GAA-repeat expansions in the FXN gene, reducing frataxin and impairing mitochondrial iron handling and oxidative stress defense. It typically begins in childhood or adolescence with progressive gait and limb ataxia, dysarthria, sensory loss, scoliosis, diabetes, and hypertrophic cardiomyopathy, the leading cause of death. For decades management was purely symptomatic and rehabilitative, with numerous antioxidant and mitochondrial candidates (idebenone, coenzyme Q10, vitamin E, deferiprone) failing to show durable benefit. The landscape changed in February 2023 when the FDA approved omaveloxolone (Skyclarys), an Nrf2 activator, as the first-ever disease-directed therapy, based on the MOXIe trial using the modified Friedreich's Ataxia Rating Scale (mFARS). The approval validated Nrf2/antioxidant-response modulation as a target and energized a pipeline of gene-therapy, frataxin-restoration, and combination approaches now in active clinical development, while symptomatic care for cardiomyopathy, diabetes, scoliosis, and mobility remains essential alongside any disease-directed therapy.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Omaveloxolone (Skyclarys) | 2023 | Patients aged 16+ with Friedreich's ataxia (first-ever approved disease therapy) | MOXIe Part 2 (randomized, double-blind, placebo-controlled) | Change in modified Friedreich's Ataxia Rating Scale (mFARS) at 48 weeks | Placebo-corrected mFARS difference of approximately -1.55 points favoring omaveloxolone (lower = less impairment) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in friedreich's ataxia development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Idebenone — Phase 3 double-blind placebo-controlled trial (IONIA and related studies, ~2010) | Failed to meet neurological/ICARS primary endpoints; not approved for FA in the US | Antioxidant/electron-transport mechanism insufficient to alter core neurological progression; endpoint sensitivity issues |
| Deferiprone (iron chelator) — FACOMS/exploratory iron-chelation studies | No meaningful benefit; higher doses associated with worsening ataxia | Removing mitochondrial iron did not restore frataxin function and risked depleting needed iron pools |
Choosing the right endpoint
Primary endpoints that matter in friedreich's ataxia trials
- mFARS (modified Friedreich's Ataxia Rating Scale) — Primary neurological outcome in MOXIe; measures bulbar, limb, and upright-stability function
- ICARS/SARA ataxia scales — Older/alternative composite ataxia severity measures used in prior trials
- Frataxin levels — Molecular biomarker for frataxin-restoration and gene-therapy programs
- Activities of Daily Living (ADL) / Functional staging — Patient-relevant secondary measures of disability progression
- Cardiac measures (echocardiography) — Important given hypertrophic cardiomyopathy as major cause of mortality
How iNGENū runs friedreich's ataxia trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Friedreich's Ataxia clinical trials — FAQs
What was the first FDA-approved treatment for Friedreich's ataxia?
How does omaveloxolone work?
Does omaveloxolone cure or reverse FA?
Ready to discuss your friedreich's ataxia trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal